Crystal structures of three 4-[3-(XC6H4)-hexahydro[1,3] oxazolo[3,4-a]pyridin-1-yl]-2,8-bis(trifluoromethyl)quinolines (X = 3-MeO, 4-MeO and 4-HO)
Authors: De Souza, M.V.N.; Gonçalves, R.S.B.; Wardell, S.M.S.V.; Wardell, J.L. Source: Zeitschrift für Kristallographie, v. 228, p. 359-368, 2013 Publisher: De Gruyter Abstract The crystal structures of three racemic 4-{3- (X-phenyl)hexahydro[1,3]oxazolo[3,4-a]pyridin-1-yl}-2,8- bis (trifluoromethyl)quinolines, 2, namely (2: X = 3-MeO, 4-MeO and 4-HO), prepared from mefloquine and XC6H5CHO, are reported. All three molecules were previously reported to […]
The Relevance of New Drug Combinations for Modern Tuberculosis Treatment – A Patent Perspective.
Authors: Pinheiro, A.C.; De Souza, M.V.N Source: Recent Patent Reviews on Anti-Infective Drug Discovery, v. 8, p. 130-138, 2013 Publisher: Bentham Science Abstract Drug combinations (DCs) have been successfully used in different kinds of diseases such as cancer, AIDS, malaria, infectious diseases, asthma, diarrhea, hypertension, neurological disorders, among others. In this context, an important concept […]
